Clinical Trial Update: 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tanespimycin (17-AAG) in metastatic prostate cancer that did not respond to prior hormone therapy. Results were posted in 2017…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-02-20